RAF1 and cancer: It has been reported that an intact Gal-1 interface of stacked dimers of H-Ras, Raf and Gal-1 as building blocks is required for Gal-1 to modulate Ras nanoclustering, thus representing a potential drug target site in cancer associated Ras-mutations [15].